Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Thyroid cancer, Hurthle cell × cediranib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Colorectal Neoplasms 2 Triple Negative Breast Neoplasms 1 Thyroid cancer, Hurthle cell 1 Thyroid Cancer, Papillary 1 Solitary Fibrous Tumor, Pleural 1 Neoplasm Metastasis 1 Mesothelioma, Malignant 1 Gliosarcoma 1 Glioblastoma 1 Fallopian Tube Neoplasms 1 Breast Neoplasms 1 Adenocarcinoma, Follicular 1

Interventions

cediranib 1 Lenalidomide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed

127 enrolled 18 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡